lundi 11 septembre 2017

Onco Actu du 11 septembre 2017 - Spécial ESMO

5.6 ESMO

ESMO 2017 Press Release: “Triggers”: a New Tool to Assess Cancer Patients’ Palliative Needs [ESMO]

ESMO 2017 Press Release: Patients Feel Psycho-social Impact of Chemo More Acutely Than Physical Side Effects [ESMO]

ESMO 2017 Press Release: Cancer Patients Struggle with Key Aspects of Clinical Trial Methodology [ESMO]

ESMO 2017 Press Release: Study Shows ESMO Magnitude of Benefit Scale Can Be Used to Grade Orphan Drugs [ESMO]

5.6.10 ESMO - Vessie

Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer [Lilly]

Merck's Keytruda extends survival edge on its bladder cancer rivals [FiercePharma]

ESMO 2017 Press Release: Ramucirumab plus Docetaxel Improves Progression-free survival in Urothelial Cancer [ESMO]

ESMO 2017 Press Release: Mature Results Favour Pembrolizumab As Second-line Treatment For Bladder Cancer [ESMO]

ESMO 2017: Pembrolizumab Continues to Show Greater Benefit over Chemotherapy in Recurrent, Advanced Urothelial Carcinoma [ESMO]

ESMO 2017: Ramucirumab Improves PFS in Patients with Platinum Refractory Advanced Urothelial Carcinoma [ESMO]

5.6.11 ESMO- Rein

Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 [Exelixis]

Bristol-Myers' Opdivo-Yervoy cocktail slashes kidney cancer death risk by 37% [FiercePharma]

Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate -214 Trial [BMS]

ESMO 2017: Progression-free Rate Unaffected by Sequence of Cytoreductive Nephrectomy and Sunitinib in Patients with Synchronous mRCC [ESMO]

Bristol-Myers posts data on an upset checkpoint combo victory in frontline kidney cancer [EndPoints]

ESMO 2017: Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC [ESMO]

Bristol's drug cocktail cuts kidney cancer death risk 37 percent [Reuters]

5.6.12 ESMO - Observation

ESMO 2017 Press Release: Study Identifies Factors that Limit Work Ability of Young Adult Cancer Survivors [ESMO]

5.6.13 ESMO - Prostate

New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer [Janssen]

Prospective analysis reveals patients with mCRPC and germline mutations in DNA repair genes have a trend to poorer outcomes [ESMO]

ESMO 2017: Germline Mutations in DNA Repair Genes Lowers Survival in mCRPC [ESMO]

ESMO 2017: Adding Abiraterone Acetate or Docetaxel Plus Prednisone to Standard of Care in Patients with High-Risk Prostate Cancer [ESMO]

Two treatments for advanced prostate cancer bring equal benefits [Cancer Research UK]

5.6.14 ESMO - Ovaire

ESMO 2017: Patients with Platinum Sensitive Ovarian Cancer Maintan QoL During Maintenance Niraparib Therapy [ESMO]

ESMO 2017: Rucaparib Shows Clinical Benefit as Maintenance Therapy in Patients with Recurrent Ovarian Cancer [ESMO]

ESMO 2017: Overall Survival Benefit is Seen with Olaparib in Patients with Ovarian Cancer and TP53 Disruptive Mutation Status [ESMO]

Targeted drug helps keep some advanced ovarian cancers at bay [Cancer Research UK]

5.6.15 ESMO - VADS

ESMO 2017 Press Release: KEYNOTE-040 Evaluates Pembrolizumab in Head and Neck Cancer [ESMO]

5.6.16 ESMO - Appareil digestif

ESMO 2017: Pembrolizumab Demonstrates Antitumour Activity in Advanced Gastric Cancer as Monotherapy and Combined with Chemotherapy [ESMO]

ESMO 2017: Promising Results Demonstrated with DCC-2618 in GIST [ESMO]

ESMO 2017: Adjuvant Imatinib Recommended Only for Patients with High-risk GIST [ESMO]

5.6.17 ESMO - Foie

ESMO 2017: Biomarker Analysis Reveals Different Genes are Upregulated After Lenvatinib and Sorafenib Treatment in Unresected HCC [ESMO]

5.6.18 - Hémato

ESMO 2017: Patients Receiving Radioactive Iodine for Well-Differentiated Thyroid Cancer Have an Increased Risk of AML [ESMO]

ESMO 2017: Biosimilar Rituximab Shows Equivalent Efficacy to Reference Rituximab in Previously Untreated Advanced Follicular Lymphoma [ESMO]

5.6.2 ESMO - Divers

ESMO 2017: Tumour Subtype Specific Genetic Alterations Detected by Comprehensive Genomic Profiling [ESMO]

ESMO 2017: Clinical Trial Toxicity Reporting by Investigators May Not Reflect Patients’ Viewpoint [ESMO]

ESMO 2017: Subtypes of Thymic Carcinomas Show Different Genomic Alterations and Tumour Mutational Burden [ESMO]

ESMO 2017: Large Dataset of Targetable Genomic Alterations Created Using Liquid Biopsy [ESMO]

ESMO 2017 Press Release: Abdominal Fat a Key Cancer Driver for Postmenopausal Women [ESMO]

ESMO 2017 Press Release: Combination Immunotherapy in Second/third Line Extends Mesothelioma Survival to 15 Months [ESMO]

ESMO 2017 Press Release: Licensing and Reimbursement Discrepancies Impact Patient Access to Cancer Treatment [ESMO]

5.6.4 ESMO - Poumon

AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients [STAT]

Merck piles on the positive Keytruda-chemo combo results in lung cancer [FiercePharma]

AstraZeneca's Tagrisso bests rivals at holding off EGFR lung cancer growth [FiercePharma]

AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer [FiercePharma]

ESMO 2017 Press Release: Osimertinib Improves Progression-free Survival in Patients with EGFR Mutated Lung Cancer [ESMO]

ESMO 2017: Durvalumab as Consolidation Therapy Prolongs PFS in Stage III NSCLC Patients Without Progression Following Platinum-based Chemoradiotherapy [ESMO]

#ESMO17: AstraZeneca salves stinging setback with a big win in a blockbuster segment of the lung cancer market [EndPoints]

ESMO 2017: Improved Survival Demonstrated with NSCLC-chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma with RB1 Wild-type [ESMO]

ESMO 2017: First-line Dabrafenib and Trametinib Shows Substantial Clinical Activity in BRAF V600E–mutated Metastatic NSCLC [ESMO]

ESMO 2017: Front-Line Osimertinib Poised to Become Standard of Care in EGFR-Mutation Positive NSCLC [ESMO]

AstraZeneca rebuilds cancer drug hopes with new lung data [Reuters]

5.6.5 ESMO - Mélanome & Peau

Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Stud [BMS]

With Yervoy-beating data, Opdivo poised to fight melanoma's return after surgery [FiercePharma]

Merck, Incyte chalk up promising melanoma data for Keytruda-epacadostat combo [FiercePharma]

Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma [Roche]

ESMO 2017 Press Release: Combination Targeted Adjuvant Therapy Doubles Relapse-free Survival in Stage III Melanoma [ESMO]

After melanoma surgery, Bristol's Opdivo offers new care standard [Reuters]

ESMO 2017 Press Release: Adjuvant Nivolumab Superior to Ipilimumab in Surgically Resected Stage III/IV Melanoma [ESMO]

Novartis posts a win, Roche a flop in skin cancer trials [Reuters]

5.6.6 ESMO - Sein

ESMO 2017: Combined Letrozole plus Palbociclib is not Better than Chemotherapy as Neoadjuvant Treatment in Luminal Breast Cancer [ESMO]

ESMO 2017: Invasive DFS Rates Following Trastuzumab are Improved with Neratinib Over Placebo in Early Stage HER2-positive Breast Cancer [ESMO]

ESMO 2017: Combined Taselisib and Letrozole Improves Response in Postmenopausal Women with ER-positive, HER-negative Early Breast Cancer [ESMO]

Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress [ESMO]

Lilly pads case for third-to-market abemaciclib with more positive breast cancer data [FiercePharma]

ESMO 2017: TIL Levels Signal Pembrolizumab Response in Metastatic TNBC [ESMO]

ESMO 2017: Promising Response Rates in Patients with Metastatic TNBC Treated with Nivolumab After Induction Treatment [ESMO]

ESMO 2017: Combined Abemaciclib with NSAI Show Significant Clinical Benefit as Initial Treatment for Patients with HR-positive/HER2-negative ABC at Interim Analysis [ESMO]

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage [EndPoints]

ESMO 2017: Strong Association Exists Between Tumour Type and Survival in Early Breast Cancer [ESMO]

ESMO 2017: Genomic Landscape of Patients with TNBC and Disease Recurrence Investigated [ESMO]

ESMO 2017 Press Release: Abemaciclib Initial Therapy Improves Outcome in Endocrine-sensitive Advanced Breast Cancer [ESMO]

Lilly takes on Pfizer, Novartis with new breast cancer drug data [Reuters]

5.6.7 ESMO - Immunothérapies

ESMO 2017: PD-L1 as a Prognostic Factor in Patients with Glioblastoma [ESMO]

ESMO 2017: Combined Nivolumab and Radiotherapy ± Temozolomide Is Safe in Patients With Newly Diagnosed Glioblastoma [ESMO]

ESMO 2017: First KEYNOTE-028 Report of Pembrolizumab Activity in Patients with PD-L1-positive pNETs and Carcinoid Tumours [ESMO]

Cancer mutation gains ground as test for immunotherapy drugs [Reuters]

5.6.8 ESMO - Côlon-rectum

ESMO 2017: Location of the Primary Tumour, but not KRAS Mutations, May Indicate SIRT Survival Benefit in mCRC [ESMO]

5.6.9 ESMO - Col de l'utérus

Seattle Genetics Highlights Promising Data with Tisotumab Vedotin in Cervical Cancer at ESMO 2017 Congress [Seatlle Genetics]

ESMO 2017: Sub-study of the GAND-Emesis Trial with Neurokinin-1 Receptor Antagonist During Concomitant Chemoradiotherapy for Cervical Cancer [ESMO]

ESMO 2017 Press Release: Study Confirms Chemoradiation is Best Treatment for Locally Advanced Cervical Cancer [ESMO]